iHealthScreen's iPredict™ Receives MHRA Certification, Bringing AI-Powered Eye Disease Detection to the UK

December 7, 2023: iHealthScreen Inc. has announced a significant milestone with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) granting its iPredict™ system the coveted CE certification. This paves the way for the automated AI-powered technology to revolutionize early diagnosis of diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma in the UK.

iPredict™ offers a rapid and efficient solution for early detection of these eye diseases, which can lead to vision loss if left untreated. The system works by analyzing high-resolution images of the retina captured using a standard color fundus camera. Within a minute, iPredict™ generates a comprehensive report, highlighting any abnormalities and recommending appropriate follow-up actions.

Benefits of iPredict™:

• Early detection: Early diagnosis of eye diseases is crucial for preventing vision loss. iPredict™ can identify subtle changes in the retina, allowing for timely intervention.
• Improved accessibility: iPredict™ can be easily implemented in various healthcare settings, including primary care clinics, ophthalmology practices, and remote locations. This increases accessibility to eye screening, particularly for underserved communities.
• Reduced costs: iPredict™ offers a cost-effective solution compared to traditional methods of eye disease diagnosis. This can lead to significant savings for healthcare systems and patients.
• Enhanced workflow: iPredict™ automates the tedious task of analyzing retinal images, freeing healthcare professionals to focus on patient care.

MHRA Certification:

The MHRA certification signifies that iPredict™ meets the highest safety and efficacy standards. This rigorous process evaluated the system’s performance, accuracy, and reliability. This certification paves the way for iPredict™ to be used in the UK, offering a valuable tool for healthcare professionals and improving patients’ lives with eye diseases.

Impact on UK Healthcare:

The introduction of iPredict™ holds immense potential for the UK healthcare system. By enabling early and accurate diagnosis of eye diseases, the system can:

• Reduce the burden on ophthalmologists and optometrists by prioritizing referrals for patients with the highest need.
• Improve patient outcomes by initiating timely treatment and preventing vision loss.
• Lower healthcare costs by avoiding unnecessary interventions and complications.

iHealthScreen’s commitment to innovation and patient care is evident in the development of iPredict™. With MHRA certification, this groundbreaking technology is poised to transform eye care in the UK, making early diagnosis of potentially blinding diseases more accessible and efficient.